Abbott sales

Without surging sales of COVID-19 tests, Abbott Laboratories’ 8 percent second-quarter revenue decline would have been twice as bad.

*Includes $615 million in COVID-19 diagnostic testing sales. **Includes cardiovascular, neuromodulation and diabetes care.

Source: SEC filings Get the data